Apollomics EPS

What does Apollomics do? Apollomics Inc is a clinical-stage biotechnology company based in Foster City, California, operating within the Health Care sector. The company went public via an IPO on November 26, 2021, and is listed under the ticker APLM with ISIN KYG0411D1236. Apollomics focuses on the discovery and development of oncology therapies designed to address unmet medical needs. The company's pipeline includes approximately nine drug candidates, six of which are in clinical development. Its lead program involves vebreltinib (APL-101), a c-Met inhibitor being evaluated in a Phase II multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. Another key candidate is uproleselan (APL-106), an E-Selectin antagonist under development as an adjunct to standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Apollomics aims to create therapies that can be combined with existing treatments to enhance immune system engagement and target specific molecular pathways in cancer. The company's website is www.apollomicsinc.com. Apollomics is engaged in advancing innovative oncology treatments through clinical research and development. Apollomics is one of the most popular companies on Eulerpool.